Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ALID Stock Summary
In the News
Allied Corp Announces Signing of Supply Contracts of 85,000, 40,000 and 24,000 Kilograms for the 2022 Calendar Year
KELOWNA, British Columbia, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Allied Corp . ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the signing of supply contracts for the 2022 calendar. Allied will be only providing cannabis flower after the Colombian government allows it and will provide supply only to countries where it is legal to sell into (for example, the United States only allows for THC levels to be less than 0.3%).
Allied Corp Announces Approval of Research and Plant Breeding License for Psychoactive and Non-Psychoactive Cannabis in Colombia
KELOWNA, British Columbia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Allied Corp . ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce that is has been granted additional licensing that enables the Company to function as a research and plant breeding unit for psychoactive and non-psychoactive Cannabis in Colombia.
Allied Corp Provides Results of Recent Third Party Audit Confirming Production Costs and Optimization of Production
KELOWNA, British Columbia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Allied Corp . ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the results of a third party audit that was conducted at the Allied Colombian Campus. The focus of the audit was Allied's cost of production, inventory control and optimization of its production approach.
Allied Corp. Announces Approval of Second CBD Isolate Import Permit for Australia and Submits Application for the Import of Dried Cannabis
KELOWNA, British Columbia., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Allied Corp . ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce that it has received approval of a second import permit for export of CBD isolate produced at Allied's Colombian campus that is destined for the Australian market.
Allied Corp Provides Update Regarding Nevada Building and Option to Purchase Nevada State License
KELOWNA, British Columbia, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Allied Corp . ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce that it has completed the construction of its 8900 square foot modular building that is currently situated in the City of North Las Vegas. In addition to this, the City of North Las Vegas has now approved the land use for the intended location of the building. This building is awaiting the Nevada State engineering approvals in order to proceed with the building permit and then go to tender for trades to be able to complete the foundation upon which the building will be placed.
Allied Corp. Advances Psilocybin Product Psilonex™ RX and Initiates Manufacturing Process
KELOWNA, British Columbia, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Allied Corp . ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce that it has initiated the manufacturing activities for Psilonex™ RX – Allied's proprietary psilocybin product. On June 29, 2021, Allied announced its manufacturing agreement with HAVN Life Sciences to manufacture Psilonex™ RX under their legal licenses and manufacturing process.
Allied Corp. Initiates Additional Shipment of 200kgs of CBD Distillate From Colombia to Nevada, United States
KELOWNA, British Columbia, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Allied Corp . ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce that it has received approval from the Colombian Ministry of Justice to initiate a shipment of 200kgs of extracted CBD distillate product (containing less than 0.3% THC) to the United States. This shipment is specifically destined for the State of Nevada, which includes Las Vegas and Reno, and represents Allied's largest shipment of CBD distillate product (containing less than 0.3% THC) to date.
Allied Corp. Signs Additional Supply Contracts for the Export of Cannabis Flower and CBD Isolate From Colombia to Australia
KELOWNA, British Columbia, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Allied Corp . ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce that it has secured two agreements with one of the Australian medicinal cannabis companies that has received Major Project Status from the Australian Department of Industry, Science and Technology. Allied has signed two binding agreements with this company to supply initially 5 kilograms of CBD isolate, as well as a second agreement to supply 5 kilograms of cannabis flower, both of which we believe are moving towards monthly contracts with increased volumes. This agreement to supply cannabis flower is the first of its kind that Allied has signed following the announcement by the Colombian Government regarding the approval to export Colombian produced cannabis flower.
Allied Corp Initiates Additional Commercial CBD Shipment From Colombia Destined for Colorado, United States
KELOWNA, British Columbia, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) an international medical company focused on creating and providing health solutions to address today's medical mental health issues is pleased to announce that it has initiated its second commercial shipment of cannabidiol (“CBD”) (containing less than 0.3% THC) from Colombia into the United States, specifically to the State of Colorado.
Allied Corp Completes Commercial CBD Shipments From Colombia Into Australia
KELOWNA, British Columbia, July 29, 2021 (GLOBE NEWSWIRE) -- Allied Corp . ("Allied" or the “Company”) (OTCQB: ALID) an international medical company focused on creating and providing health solutions to address today's medical mental health issues is pleased to announce that it has completed its commercial shipments of cannabidiol (“CBD”) isolate from Colombia to Australia. This purchase agreement is intended to continue with a monthly supply contract.
ALID Financial details
ALID Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-08-31
Metric | History | 2019-03-31 | 2020-08-31 | 2021-08-31 | 2022-08-31 | 2023-08-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0 | -0.08 | -0.15 | -0.18 | -0.11 | |
Operating cash flow per share | 0 | -0.04 | -0.05 | -0.05 | -0.02 | |
Free cash flow per share | 0 | -0.04 | -0.05 | -0.06 | -0.02 | |
Cash per share | 0 | 0 | 0.01 | 0 | 0 | |
Book value per share | 0 | 0.05 | -0.01 | -0.01 | -0.07 | |
Tangible book value per share | 0 | 0.01 | -0.01 | -0.02 | -0.07 | |
Share holders equity per share | 0 | 0.05 | -0.01 | -0.01 | -0.07 | |
Interest debt per share | 0 | 0.03 | 0.05 | 0.07 | 0.07 | |
Market cap | 108.32M | 125.16M | 86.02M | 42.37M | 22.75M | |
Enterprise value | 108.32M | 127.07M | 89.33M | 47.35M | 28.4M | |
P/E ratio | -4.69K | -18.51 | -7.07 | -2.53 | -2.13 | |
Price to sales ratio | 0 | 0 | 6.87K | 255.83 | 315.52 | |
POCF ratio | -8.57K | -39.6 | -21.74 | -9.89 | -11.62 | |
PFCF ratio | -8.57K | -38.25 | -20.58 | -7.72 | -11.13 | |
P/B Ratio | -1.81K | 33.79 | -88.61 | -33.04 | -3.3 | |
PTB ratio | -1.81K | 33.79 | -88.61 | -33.04 | -3.3 | |
EV to sales | 0 | 0 | 7.14K | 285.93 | 393.91 | |
Enterprise value over EBITDA | -4.69K | -41.79 | -12.67 | -3.33 | -4.24 | |
EV to operating cash flow | -8.57K | -40.2 | -22.58 | -11.05 | -14.51 | |
EV to free cash flow | -8.57K | -38.83 | -21.37 | -8.63 | -13.89 | |
Earnings yield | 0 | -0.05 | -0.14 | -0.4 | -0.47 | |
Free cash flow yield | 0 | -0.03 | -0.05 | -0.13 | -0.09 | |
Debt to equity | 0 | 0.54 | -3.85 | -3.96 | -0.85 | |
Debt to assets | 0 | 0.28 | 0.81 | 0.88 | 2.84 | |
Net debt to EBITDA | 0 | -0.63 | -0.47 | -0.35 | -0.84 | |
Current ratio | 0 | 0.06 | 0.17 | 0.18 | 0.05 | |
Interest coverage | 0 | -23.66 | -12.15 | -11.59 | -11.89 | |
Income quality | 0.55 | 0.48 | 0.34 | 0.28 | 0.18 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 464.09 | 86.02 | 72.4 | |
Research and developement to revenue | 0 | 0 | 0 | 0.07 | 0 | |
Intangibles to total assets | 0 | 0.46 | 0.04 | 0.03 | 0.02 | |
Capex to operating cash flow | 0 | 0.04 | 0.06 | 0.28 | 0.04 | |
Capex to revenue | 0 | 0 | -17.88 | -7.28 | -1.22 | |
Capex to depreciation | 0 | -0.24 | -0.41 | -14.59 | -0.64 | |
Stock based compensation to revenue | 0 | 0 | 212.98 | 44.2 | 42.27 | |
Graham number | 0 | 0.29 | 0.2 | 0.24 | 0.42 | |
ROIC | 0.39 | -0.59 | -2.67 | -3.87 | 12.14 | |
Return on tangible assets | -224.35 | -1.78 | -2.74 | -3 | -5.28 | |
Graham Net | 0 | -0.04 | -0.06 | -0.07 | -0.09 | |
Working capital | -59.8K | -2.87M | -4.47M | -5.67M | -8.38M | |
Tangible asset value | -59.8K | 404.16K | -1.17M | -1.48M | -6.92M | |
Net current asset value | -59.8K | -3.2M | -4.69M | -5.83M | -8.48M | |
Invested capital | 0 | 0.54 | -3.85 | -3.96 | -0.85 | |
Average receivables | 0 | 0 | 41.42K | 102.13K | 127.96K | |
Average payables | 9.98K | 705.86K | 698.25K | 803.93K | 2M | |
Average inventory | 0 | 26.29K | 94.42K | 567.62K | 553.25K | |
Days sales outstanding | 0 | 0 | 2.42K | 267.65 | 680.84 | |
Days payables outstanding | 0 | 5.63K | 0 | 6.42K | 569.53 | |
Days of inventory on hand | 0 | 212 | 77.96 | 3.99K | 25.58 | |
Receivables turnover | 0 | 0 | 0.15 | 1.36 | 0.54 | |
Payables turnover | 0 | 0.06 | 0 | 0.06 | 0.64 | |
Inventory turnover | 0 | 1.72 | 4.68 | 0.09 | 14.27 | |
ROE | 0.39 | -1.83 | 12.53 | 13.08 | 1.55 | |
Capex per share | 0 | 0 | 0 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-08-31 for Q4
Metric | History | 2022-08-31 | 2022-11-30 | 2023-02-28 | 2023-05-31 | 2023-08-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.01 | -0.02 | -0.02 | -0.02 | -0.05 | |
Operating cash flow per share | -0.01 | -0.01 | -0.01 | 0 | 0 | |
Free cash flow per share | -0.01 | -0.01 | -0.01 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | -0.02 | -0.02 | -0.02 | -0.02 | -0.07 | |
Tangible book value per share | -0.02 | -0.02 | -0.02 | -0.03 | -0.07 | |
Share holders equity per share | -0.02 | -0.02 | -0.02 | -0.02 | -0.07 | |
Interest debt per share | 0.07 | 0.06 | 0.06 | 0.06 | 0.06 | |
Market cap | 36.98M | 26.89M | 29.16M | 26.02M | 22.75M | |
Enterprise value | 41.96M | 32.05M | 34.66M | 31.81M | 28.4M | |
P/E ratio | -11.16 | -4.45 | -3.53 | -3 | -1.11 | |
Price to sales ratio | 317.66 | 386.18 | 0 | 0 | 9.21K | |
POCF ratio | -35.94 | -45.12 | -25.81 | -91.44 | 426.29 | |
PFCF ratio | -36.89 | -40.61 | -25.39 | -91.22 | 445.17 | |
P/B Ratio | -28.84 | -17.96 | -14.22 | -10.84 | -3.3 | |
PTB ratio | -28.84 | -17.96 | -14.22 | -10.84 | -3.3 | |
EV to sales | 360.47 | 460.27 | 0 | 0 | 11.49K | |
Enterprise value over EBITDA | -37.77 | -30.3 | -19.01 | -13.84 | -12.39 | |
EV to operating cash flow | -40.78 | -53.78 | -30.68 | -111.79 | 532.2 | |
EV to free cash flow | -41.87 | -48.4 | -30.19 | -111.52 | 555.78 | |
Earnings yield | -0.02 | -0.06 | -0.07 | -0.08 | -0.23 | |
Free cash flow yield | -0.03 | -0.02 | -0.04 | -0.01 | 0 | |
Debt to equity | -3.96 | -3.52 | -2.76 | -2.41 | -0.85 | |
Debt to assets | 0.88 | 0.9 | 0.93 | 0.93 | 2.84 | |
Net debt to EBITDA | -4.49 | -4.88 | -3.02 | -2.52 | -2.47 | |
Current ratio | 0.18 | 0.2 | 0.21 | 0.21 | 0.05 | |
Interest coverage | -6.17 | -5.37 | -9.45 | -10.2 | -9.75 | |
Income quality | 2.06 | 0.46 | 0.55 | 0.13 | -0.01 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 9.98 | 15.71 | 0 | 0 | 317.43 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.03 | 0.01 | 0.01 | 0.01 | 0.02 | |
Capex to operating cash flow | -0.03 | 0.11 | 0.02 | 0 | -0.04 | |
Capex to revenue | 0.23 | -0.95 | 0 | 0 | -0.92 | |
Capex to depreciation | -0.56 | -2.53 | -0.6 | -0.02 | -0.05 | |
Stock based compensation to revenue | 4.05 | 7.83 | 0 | 0 | 79.91 | |
Graham number | 0.06 | 0.07 | 0.1 | 0.11 | 0.29 | |
ROIC | -0.44 | -0.32 | -0.52 | -0.67 | 2.68 | |
Return on tangible assets | -0.15 | -0.26 | -0.34 | -0.35 | -2.54 | |
Graham Net | -0.08 | -0.07 | -0.07 | -0.08 | -0.09 | |
Working capital | -5.67M | -5.81M | -6.32M | -6.7M | -8.38M | |
Tangible asset value | -1.48M | -1.54M | -2.09M | -2.44M | -6.92M | |
Net current asset value | -5.83M | -5.96M | -6.46M | -6.84M | -8.48M | |
Invested capital | -3.96 | -3.52 | -2.76 | -2.41 | -0.85 | |
Average receivables | 67.96K | 111.79K | 114.81K | 133.14K | 136.65K | |
Average payables | -1.89B | 1.68M | 1.88M | 2.12M | 2.31M | |
Average inventory | 614.33K | 1.09M | 1.29M | 1.51M | 868.63K | |
Days sales outstanding | 93.88 | 132.05 | 0 | 0 | 4.9K | |
Days payables outstanding | 2.91K | 6.05K | 0 | 0 | 142.85 | |
Days of inventory on hand | 1.81K | 4.12K | 0 | 0 | 6.42 | |
Receivables turnover | 0.96 | 0.68 | 0 | 0 | 0.02 | |
Payables turnover | 0.03 | 0.01 | 0 | 0 | 0.63 | |
Inventory turnover | 0.05 | 0.02 | 0 | 0 | 14.03 | |
ROE | 0.65 | 1.01 | 1.01 | 0.9 | 0.75 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
ALID Frequently Asked Questions
What is Allied Corp. stock symbol ?
Allied Corp. is a CA stock , located in Kelowna of Bc and trading under the symbol ALID
What is Allied Corp. stock quote today ?
Allied Corp. stock price is $0.065 today.
Is Allied Corp. stock public?
Yes, Allied Corp. is a publicly traded company.